JP2004508366A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004508366A5 JP2004508366A5 JP2002525134A JP2002525134A JP2004508366A5 JP 2004508366 A5 JP2004508366 A5 JP 2004508366A5 JP 2002525134 A JP2002525134 A JP 2002525134A JP 2002525134 A JP2002525134 A JP 2002525134A JP 2004508366 A5 JP2004508366 A5 JP 2004508366A5
- Authority
- JP
- Japan
- Prior art keywords
- dihydro
- solvate
- salt
- functional derivative
- physiologically functional
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- KMHXVUCYJPXSIV-DHDCSXOGSA-N (3z)-3-[[4-(1,2,4-triazol-1-yl)anilino]methylidene]-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C\NC(C=C1)=CC=C1N1C=NC=N1 KMHXVUCYJPXSIV-DHDCSXOGSA-N 0.000 claims 1
- XAHMAJJMFALGCW-ZROIWOOFSA-N (3z)-3-[[4-(1h-1,2,4-triazol-5-yl)anilino]methylidene]-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C\NC(C=C1)=CC=C1C=1N=CNN=1 XAHMAJJMFALGCW-ZROIWOOFSA-N 0.000 claims 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical group C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims 1
- HSHFQBBHYFYCQC-LGMDPLHJSA-N 3-ethyl-3-[4-[[(z)-(2-oxo-1h-indol-3-ylidene)methyl]amino]phenyl]piperidine-2,6-dione Chemical compound C=1C=C(N\C=C/2C3=CC=CC=C3NC\2=O)C=CC=1C1(CC)CCC(=O)NC1=O HSHFQBBHYFYCQC-LGMDPLHJSA-N 0.000 claims 1
- WPAUHINVDSQAEQ-FLIBITNWSA-N 5-[[(z)-(2-oxo-1h-indol-3-ylidene)methyl]amino]-1,3-dihydrobenzimidazol-2-one Chemical compound C1=C2NC(=O)NC2=CC(N/C=C2/C3=CC=CC=C3NC2=O)=C1 WPAUHINVDSQAEQ-FLIBITNWSA-N 0.000 claims 1
- 101150111783 NTRK1 gene Proteins 0.000 claims 1
- JUULZRNMGDKYCG-YFHOEESVSA-N O1C(N)=NN=C1C1=CC=CC(N\C=C/2C3=C4N=NNC4=CC=C3NC\2=O)=C1 Chemical compound O1C(N)=NN=C1C1=CC=CC(N\C=C/2C3=C4N=NNC4=CC=C3NC\2=O)=C1 JUULZRNMGDKYCG-YFHOEESVSA-N 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003226 mitogen Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 230000035790 physiological processes and functions Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22996600P | 2000-09-01 | 2000-09-01 | |
| PCT/US2001/026286 WO2002020513A1 (en) | 2000-09-01 | 2001-08-23 | Oxindole derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004508366A JP2004508366A (ja) | 2004-03-18 |
| JP2004508366A5 true JP2004508366A5 (enExample) | 2005-05-19 |
Family
ID=22863416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002525134A Pending JP2004508366A (ja) | 2000-09-01 | 2001-08-23 | オキシインドール誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US6964977B2 (enExample) |
| EP (1) | EP1317446A1 (enExample) |
| JP (1) | JP2004508366A (enExample) |
| AU (1) | AU8664701A (enExample) |
| WO (1) | WO2002020513A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9904933D0 (en) * | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Compounds |
| WO2004032870A2 (en) | 2002-10-08 | 2004-04-22 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same |
| US7255860B2 (en) | 2002-10-08 | 2007-08-14 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody |
| US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
| DK1575517T3 (da) | 2002-12-24 | 2012-05-14 | Rinat Neuroscience Corp | Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| JP4938447B2 (ja) | 2003-06-23 | 2012-05-23 | シエル・インターナシヨネイル・リサーチ・マーチヤツピイ・ベー・ウイ | 潤滑基油の製造方法 |
| KR101637908B1 (ko) | 2004-04-07 | 2016-07-11 | 리나트 뉴로사이언스 코프. | 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법 |
| WO2005118551A2 (en) * | 2004-05-28 | 2005-12-15 | Ligand Pharmaceuticals Inc. | Thrombopoietin activity modulating compounds and methods |
| DE602005024599D1 (de) * | 2004-10-25 | 2010-12-16 | Ligand Pharm Inc | Verbindungen modulierende thrombopoietinaktivität und verfahren |
| DK2383268T3 (en) | 2005-02-04 | 2015-09-14 | Astrazeneca Ab | PYRAZOLYLAMINOPYRIDINDERIVATER useful as kinase inhibitors |
| KR101362621B1 (ko) | 2005-02-16 | 2014-02-13 | 아스트라제네카 아베 | 화합물 |
| CA2608009A1 (en) | 2005-05-16 | 2006-11-23 | Astrazeneca Ab | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
| BRPI0618011A2 (pt) | 2005-10-28 | 2011-08-16 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito anti-proliferativo e um efeito pró-apoptósico em um animal de sangue quente, para tratar doença e para produzir um efeito inibidor de jak em um animal de sangue quente |
| JP5182088B2 (ja) | 2006-04-19 | 2013-04-10 | アステラス製薬株式会社 | アゾールカルボキサミド誘導体 |
| TW200826937A (en) * | 2006-11-01 | 2008-07-01 | Astrazeneca Ab | New use |
| SI2206707T1 (sl) | 2007-10-24 | 2014-11-28 | Astellas Pharma Inc. | Azolkarboksamidna spojina ali njena sol |
| US8426673B2 (en) | 2008-01-11 | 2013-04-23 | Astellas Pharma, Inc. | Pathological animal model for pelvic pain syndrome |
| WO2009135000A2 (en) * | 2008-04-30 | 2009-11-05 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Inhibition of shp2/ptpn11 protein tyrosine phosphatase by nsc-117199 and analogs |
| TWI585088B (zh) | 2012-06-04 | 2017-06-01 | 第一三共股份有限公司 | 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物 |
| US9718775B2 (en) * | 2014-03-14 | 2017-08-01 | Milliken & Company | Oxindole compounds and compositions comprising the same |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9718913D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| DE19824922A1 (de) * | 1998-06-04 | 1999-12-09 | Boehringer Ingelheim Pharma | Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
| GB9904933D0 (en) | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Compounds |
| US6624171B1 (en) * | 1999-03-04 | 2003-09-23 | Smithkline Beecham Corporation | Substituted aza-oxindole derivatives |
| US6498176B1 (en) * | 1999-03-04 | 2002-12-24 | Smithklinebeecham Corporation | 3-(anilinomethylene) oxindoles as protein tyrosine kinase and protein serine/threonine kinase inhibitors |
| US6492398B1 (en) * | 1999-03-04 | 2002-12-10 | Smithkline Beechman Corporation | Thiazoloindolinone compounds |
| US6620818B1 (en) * | 2000-03-01 | 2003-09-16 | Smithkline Beecham Corporation | Method for reducing the severity of side effects of chemotherapy and/or radiation therapy |
| US7015231B2 (en) | 2001-09-27 | 2006-03-21 | Smithkline Beecham Corporation | Chemical compounds |
-
2001
- 2001-08-23 WO PCT/US2001/026286 patent/WO2002020513A1/en not_active Ceased
- 2001-08-23 AU AU8664701A patent/AU8664701A/xx active Pending
- 2001-08-23 EP EP01966107A patent/EP1317446A1/en not_active Withdrawn
- 2001-08-23 US US10/362,739 patent/US6964977B2/en not_active Expired - Fee Related
- 2001-08-23 JP JP2002525134A patent/JP2004508366A/ja active Pending
-
2005
- 2005-08-03 US US11/196,597 patent/US20050282810A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7216682B2 (ja) | Ｕｓｐ３０阻害剤としての１－シアノ－ピロリジン化合物 | |
| TWI699359B (zh) | ４ｈ-吡咯［３,２-ｃ］吡啶-４-酮衍生物 | |
| ES2206292T3 (es) | Derivados de oxazol y tiazol como agentes activadores de la produccion/secrecion de neurotrofina. | |
| JP2020530446A5 (enExample) | ||
| JP4974438B2 (ja) | ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリンおよびキナゾリン誘導体 | |
| EP2675801B1 (en) | Novel pyrazole and imidazole derivatives useful as orexin antagonists | |
| JP5647268B2 (ja) | 新規抗真菌性トリアゾール誘導体 | |
| JP2019077725A5 (enExample) | ||
| AU2009266756B2 (en) | Triazole derivative or salt thereof | |
| US20080166359A1 (en) | Methods of using MEK inhibitors | |
| CA2799640C (en) | 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace) | |
| RU2008141761A (ru) | ИНГИБИТОРЫ с-МЕТ ПРОТЕИНКИНАЗЫ | |
| US20090137596A1 (en) | G-protein inhibitor | |
| JP4974437B2 (ja) | ファルネシルトランスフェラーゼを阻害する６−［（置換フェニル）メチル］−キノリンおよびキナゾリン誘導体 | |
| JP2005525324A5 (enExample) | ||
| RU2003107016A (ru) | Замещенные пиразолы | |
| JP2008520741A5 (enExample) | ||
| JP2002517445A (ja) | ｃＧＭＰホスホジエステラーゼのキナゾリノン抑制剤 | |
| JP2013501749A5 (enExample) | ||
| JP2004517848A (ja) | 抗ウイルス剤 | |
| JP2009528389A5 (enExample) | ||
| JP2008507539A5 (enExample) | ||
| JP2009538321A5 (enExample) | ||
| RU2006127575A (ru) | Соединение триазола и их применение в качестве антагонистов метаботропного рецептора глутамата | |
| CA2442428A1 (en) | Novel tyrosine kinase inhibitors |